- Closed total new debt and equity commitments of
$190.7 million to twelve (12) companies including eight (8) new and four (4) existing portfolio companies for Q1 2017 - Unscheduled principal repayments “early pay-offs” of
$100.3 million for Q1 2017 - Six (6) Hercules portfolio companies currently in IPO Registration
“Our first quarter 2017 portfolio activity reflects our slow and steady, conservative underwriting posture as we continue to navigate through the uncertainty of the new administration policies to be deployed, closing over
New Debt and Equity Commitments for Q1 2017:
As of March 31, 2017, Hercules has originated
Twelve (12) new commitments to innovative venture growth stage companies:
Technology Portfolio –
-
$40.0 million to a leading technology developer that provides advanced text analytics, enterprise survey and customer engagement to help hundreds of the world’s leading brands understand and improve their customer experience -
$15.0 million to a developer and pioneer of analytical devices for chemical and biomolecule analysis -
$15.0 million to a leading provider of on-demand project management software for small and midsize companies -
$3.7 million equity investment to a technology developer that provides the most complete enterprise social technology in the world, designed to help large companies collaborate across their entire organization to create intuitive, superior customer experiences across every social channel
Life Sciences Portfolio –
-
$55.0 million to a leading clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutics for the treatment of dementia -
$20.0 million to a biopharmaceutical company committed to the development and commercialization of innovative new treatments for people with serious, rare muscle diseases through the application of adeno-associated virus (AAV) gene therapy technology -
$15.0 million to a medical devices company focused on bringing innovative, cost-effective, surgical reconstruction solutions to surgeons, hospitals and patients -
$10.0 million to a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer
New Commitments to Four (4) Existing Portfolio Companies –
Unscheduled Early Principal Repayments “Early Pay-Offs:”
As of
Portfolio Company IPO, M&A and Other Activity in Q1 2017:
IPO Activities
As of
- Six (6) companies filed confidentially under the JOBS Act
There can be no assurances that companies that have yet to complete their IPOs will do so.
M&A Activities
1. In
2. In
3. In
4. In
5. In
6. In
7. In
8. In
9. In
Other Activities
1. In
About
Hercules’ common stock trades on the
In addition, Hercules has one outstanding bond issuance of 6.25% Unsecured Notes due
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. You should understand that under Section 27A(b)(2)(B) of the Securities Act of 1933, as amended, and Section 21E(b)(2)(B) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 do not apply to forward-looking statements made in periodic reports we file under the Exchange Act.
The information disclosed in this press release is made as of the date hereof and reflects Hercules most current assessment of its historical financial performance. Actual financial results filed with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20170417005332/en/
mhara@htgc.com
Source:
H.I.G. Capital Makes a Strategic Investment in Barnet Dulaney Perkins and Southwestern Eye Center
Floor & Decor Holdings, Inc. Announces Launch of Initial Public Offering
More Articles